“It has demonstrated our capability to take specific chemical entities from the conceptual phase to pre-investigational new drug status and, ultimately, to the FDA. “The ARS project is a cornerstone of the ND3P,” said Ken Bayles, co-principal investigator and UNMC vice chancellor for research. More than 77 researchers are listed in the network, which is supported by a steering committee of industry and academic leaders. This project also activated a higher-level strategy for NU that is now in full gear - the Nebraska Drug Discovery and Development Pipeline, or “ND3P.” Connecting the drug discovery and development expertise, capabilities, facilities and technologies from all four NU campuses, ND3P helps the Department of Defense explore, innovate and pursue essential but rarely used therapeutics that would not otherwise be pursued due to low profitability. Radiation Exposure Induces Cross-Species Temporal Metabolic Changes That are Mitigated in Mice by Amifostine NMR and Metabolomics - A Roadmap for the Future They also have published several papers regarding their work, including:Ī Pipeline for Multi-Omics Data Integration in Metabolic Modeling and Drug Discovery The researchers are leveraging several NU facilities and technologies and have provided real-world experiences to undergraduate and graduate students. Robert Powers, UNL Charles Bessey professor and director of the NCIBC systems biology core, metabolomics lead Massimiliano Pierobon, UNL associate professor, data analysis and simulation lead Rebecca Oberley-Deegan, UNMC professor, in vivo efficacy lead Rosowski professor, biochemistry and systems biology leadĭJ Murry, UNMC professor, pharmacokinetics and pharmacodynamics co-lead Patrick Dussault, UNL Charles Bessey professor, medicinal chemistry leadĬhittibabu Guda, UNMC professor and chief bioinformatics and research computing officer, transcriptomics lead Yashpal Chhonker, UNMC research assistant professor, pharmacokinetics and pharmacodynamics co-lead We bring a truly interdisciplinary approach to the science, leveraging the power of the UNL and UNMC collaboration.”Ī key military partner for the project is the Armed Forces Radiobiology Research Institute. “It is really a challenging space scientifically, but I think that is why our team has been so successful - we have passion for the purpose of this work. “We are looking at both prevention and mitigation strategies, and they are not necessarily the same agents,” said David Berkowitz, co-principal investigator and Willa Cather Professor of chemistry at UNL, who also currently leads the Division of Chemistry at the National Science Foundation. Having made substantial progress toward completing the initial pharmacokinetic and pharmacodynamic testing on multiple candidate compounds, the research team will continue testing candidate compounds and gathering data for evaluation and approval for use by the Food and Drug Administration. The contract also is the highest single-project award in NSRI’s history. This is the third DHA contract for this work and brings the project to more than $35 million in funding since 2017. Strategic Command and the University of Nebraska system. To launch the next steps of this important work, the Defense Health Agency has awarded a $24.5 million contract to NSRI, the Department of Defense University Affiliated Research Center of U.S. troops from the effects of acute radiation syndrome.ĪRS is caused by exposure to high levels of radiation, which could result from a dirty bomb terrorist attack, nuclear accident or nuclear weapons incident. Researchers from the University of Nebraska–Lincoln and University of Nebraska Medical Center, with guidance and administration from the National Strategic Research Institute, are advancing development of a first-of-its-kind prophylactic to help protect U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |